Published in Biochem J on February 15, 2000
Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc Natl Acad Sci U S A (2005) 3.74
Reactive oxygen species in cancer. Free Radic Res (2010) 3.20
Gene disruption discloses role of selenoprotein P in selenium delivery to target tissues. Biochem J (2003) 2.30
Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol Cell Biol (2004) 2.12
Cytoplasmic thioredoxin reductase is essential for embryogenesis but dispensable for cardiac development. Mol Cell Biol (2005) 1.80
Selenoprotein oxidoreductase with specificity for thioredoxin and glutathione systems. Proc Natl Acad Sci U S A (2001) 1.63
Genomic insights into bifidobacteria. Microbiol Mol Biol Rev (2010) 1.57
Nrf2 signaling, a mechanism for cellular stress resistance in long-lived mice. Mol Cell Biol (2009) 1.52
The human selenoproteome: recent insights into functions and regulation. Cell Mol Life Sci (2009) 1.50
Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection. Prog Neurobiol (2012) 1.41
Mitochondrial Dysfunction Plus High-Sugar Diet Provokes a Metabolic Crisis That Inhibits Growth. PLoS One (2016) 1.38
Thiol chemistry in peroxidase catalysis and redox signaling. Antioxid Redox Signal (2008) 1.35
Autophagy, redox signaling, and ventricular remodeling. Antioxid Redox Signal (2009) 1.28
Semisynthesis and characterization of mammalian thioredoxin reductase. Biochemistry (2006) 1.28
Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model. Proc Natl Acad Sci U S A (2006) 1.27
Evidence that feedback inhibition of NAD kinase controls responses to oxidative stress. Proc Natl Acad Sci U S A (2006) 1.20
Efficient selenium transfer from mother to offspring in selenoprotein-P-deficient mice enables dose-dependent rescue of phenotypes associated with selenium deficiency. Biochem J (2004) 1.19
Selenoproteins and their impact on human health through diverse physiological pathways. Physiology (Bethesda) (2006) 1.13
Effects of thioredoxin reductase-1 deletion on embryogenesis and transcriptome. Free Radic Biol Med (2007) 1.13
Thioredoxin reductase-1 knock down does not result in thioredoxin-1 oxidation. Biochem Biophys Res Commun (2008) 1.13
Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. Proc Natl Acad Sci U S A (2005) 1.13
Identification of a novel selenium-containing compound, selenoneine, as the predominant chemical form of organic selenium in the blood of bluefin tuna. J Biol Chem (2010) 1.11
The ferredoxin/thioredoxin system: from discovery to molecular structures and beyond. Photosynth Res (2002) 1.11
Role of oxidative stress and nitric oxide in atherothrombosis. Front Biosci (2008) 1.10
No selenium required: reactions catalyzed by mammalian thioredoxin reductase that are independent of a selenocysteine residue. Biochemistry (2009) 1.09
The human respiratory syncytial virus nonstructural protein 1 regulates type I and type II interferon pathways. Mol Cell Proteomics (2012) 1.08
Dissection of complex protein dynamics in human thioredoxin. Proc Natl Acad Sci U S A (2007) 1.06
Glutathione and glutaredoxin act as a backup of human thioredoxin reductase 1 to reduce thioredoxin 1 preventing cell death by aurothioglucose. J Biol Chem (2012) 1.06
A redox-dependent mechanism for regulation of AMPK activation by Thioredoxin1 during energy starvation. Cell Metab (2014) 1.03
Thioredoxin-related mechanisms in hyperoxic lung injury in mice. Am J Respir Cell Mol Biol (2007) 1.03
Mammalian thioredoxin reductase 1: roles in redox homoeostasis and characterization of cellular targets. Biochem J (2010) 1.03
The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells. Br J Pharmacol (2005) 1.02
Thioredoxin reductase is essential for viability in the fungal pathogen Cryptococcus neoformans. Eukaryot Cell (2005) 1.02
Inhibition of thioredoxin reductase 1 by caveolin 1 promotes stress-induced premature senescence. EMBO Rep (2009) 1.02
Reactive oxygen and nitrogen species induce protein and DNA modifications driving arthrofibrosis following total knee arthroplasty. Fibrogenesis Tissue Repair (2009) 1.01
A novel peroxiredoxin of the plant Sedum lineare is a homologue of Escherichia coli bacterioferritin co-migratory protein (Bcp). Biochem J (2000) 1.01
Thioredoxin reductase-1 negatively regulates HIV-1 transactivating protein Tat-dependent transcription in human macrophages. J Biol Chem (2008) 0.98
Inhibition of glutathione and thioredoxin metabolism enhances sensitivity to perifosine in head and neck cancer cells. J Oncol (2009) 0.98
The energy-redox axis in aging and age-related neurodegeneration. Adv Drug Deliv Rev (2009) 0.98
A new strategy for assessing selenoprotein function: siRNA knockdown/knock-in targeting the 3'-UTR. RNA (2007) 0.96
Penultimate selenocysteine residue replaced by cysteine in thioredoxin reductase from selenium-deficient rat liver. FASEB J (2009) 0.96
Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo. Cell Death Dis (2014) 0.95
Crystal structure of the electron transfer complex rubredoxin rubredoxin reductase of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A (2007) 0.95
Biological Effects of Space Radiation and Development of Effective Countermeasures. Life Sci Space Res (Amst) (2014) 0.94
Thioredoxin and thioredoxin reductase influence estrogen receptor alpha-mediated gene expression in human breast cancer cells. J Mol Endocrinol (2009) 0.94
Post-transcriptional defects of antioxidant selenoenzymes cause oxidative stress under methylmercury exposure. J Biol Chem (2010) 0.93
Proposed criteria for assessing the efficacy of cancer reduction by plant foods enriched in carotenoids, glucosinolates, polyphenols and selenocompounds. Ann Bot (2005) 0.93
Apurinic/apyrimidinic endonuclease 1 alters estrogen receptor activity and estrogen-responsive gene expression. Mol Endocrinol (2009) 0.93
Antiproliferative effect of gold(I) compound auranofin through inhibition of STAT3 and telomerase activity in MDA-MB 231 human breast cancer cells. BMB Rep (2013) 0.93
Selective targeting of the cysteine proteome by thioredoxin and glutathione redox systems. Mol Cell Proteomics (2013) 0.93
Signaling actions of electrophiles: anti-inflammatory therapeutic candidates. Mol Interv (2010) 0.93
Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase. Mol Cancer Ther (2006) 0.92
T cells expanded in presence of IL-15 exhibit increased antioxidant capacity and innate effector molecules. Cytokine (2011) 0.92
The NADPH-dependent thioredoxin reductase/thioredoxin system in germinating barley seeds: gene expression, protein profiles, and interactions between isoforms of thioredoxin h and thioredoxin reductase. Plant Physiol (2007) 0.92
The glutathione system of Aspergillus nidulans involves a fungus-specific glutathione S-transferase. J Biol Chem (2009) 0.90
Free radical production from the interaction of 2-chloroethyl vesicants (mustard gas) with pyridine nucleotide-driven flavoprotein electron transport systems. Toxicol Appl Pharmacol (2008) 0.90
Caveolin-1, cellular senescence and age-related diseases. Mech Ageing Dev (2011) 0.90
Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism. PLoS One (2012) 0.90
Discovery of the strong antioxidant selenoneine in tuna and selenium redox metabolism. World J Biol Chem (2010) 0.89
Protein import into hydrogenosomes of Trichomonas vaginalis involves both N-terminal and internal targeting signals: a case study of thioredoxin reductases. Eukaryot Cell (2008) 0.88
Immunohistochemical analysis of oxidative stress and DNA repair proteins in normal mammary and breast cancer tissues. BMC Cancer (2010) 0.88
Oxidative stress measured by thioredoxin reductase level as potential biomarker for prostate cancer. Am J Cancer Res (2015) 0.87
The distal sequence element of the selenocysteine tRNA gene is a tissue-dependent enhancer essential for mouse embryogenesis. Mol Cell Biol (2005) 0.87
Antineoplastic effects of gamma linolenic Acid on hepatocellular carcinoma cell lines. J Clin Biochem Nutr (2010) 0.87
Targeted disruption of glutathione peroxidase 4 in mouse skin epithelial cells impairs postnatal hair follicle morphogenesis that is partially rescued through inhibition of COX-2. J Invest Dermatol (2013) 0.87
Dietary regulation of Keap1/Nrf2/ARE pathway: focus on plant-derived compounds and trace minerals. Nutrients (2014) 0.87
Why is mammalian thioredoxin reductase 1 so dependent upon the use of selenium? Biochemistry (2014) 0.86
Interactions between genes involved in the antioxidant defence system and breast cancer risk. Br J Cancer (2006) 0.86
Glc-6-PD and PKG contribute to hypoxia-induced decrease in smooth muscle cell contractile phenotype proteins in pulmonary artery. Am J Physiol Lung Cell Mol Physiol (2012) 0.86
Organoselenium (Sel-Plex diet) decreases amyloid burden and RNA and DNA oxidative damage in APP/PS1 mice. Free Radic Biol Med (2009) 0.85
Decreased DGCR8 expression and miRNA dysregulation in individuals with 22q11.2 deletion syndrome. PLoS One (2014) 0.85
Anti-cancer activity of new designer hydrogen sulfide-donating hybrids. Antioxid Redox Signal (2013) 0.85
Thioredoxin reductase inhibition reduces relaxation by increasing oxidative stress and s-nitrosylation in mouse aorta. J Cardiovasc Pharmacol (2011) 0.85
N',N'-Dimethyl-N',N'-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS). Cancers (Basel) (2009) 0.84
Structure of Hordeum vulgare NADPH-dependent thioredoxin reductase 2. Unwinding the reaction mechanism. Acta Crystallogr D Biol Crystallogr (2009) 0.84
Expression, purification, crystallization and preliminary X-ray crystallographic studies of Deinococcus radiodurans thioredoxin reductase. Acta Crystallogr Sect F Struct Biol Cryst Commun (2006) 0.83
Cytosolic, mitochondrial thioredoxins and thioredoxin reductases in Arabidopsis thaliana. Photosynth Res (2004) 0.83
Thioredoxin reductase-1 mediates curcumin-induced radiosensitization of squamous carcinoma cells. Cancer Res (2010) 0.83
Thioredoxin reductase: a novel, independent prognostic marker in patients with hepatocellular carcinoma. Oncotarget (2015) 0.82
Proteome changes in human bronchoalveolar cells following styrene exposure indicate involvement of oxidative stress in the molecular-response mechanism. Proteomics (2009) 0.82
The subcellular location of selenoproteins and the impact on their function. Nutrients (2015) 0.82
Unveiling the roles of the glutathione redox system in vivo by analyzing genetically modified mice. J Clin Biochem Nutr (2011) 0.82
Thioredoxin system from Deinococcus radiodurans. J Bacteriol (2009) 0.82
Deciphering the magainin resistance process of Escherichia coli strains in light of the cytosolic proteome. Antimicrob Agents Chemother (2012) 0.82
Thioredoxin reductase from Thermoplasma acidophilum: a new twist on redox regulation. Biochemistry (2008) 0.82
New drug target in protozoan parasites: the role of thioredoxin reductase. Front Microbiol (2015) 0.82
Neuroprotection of antioxidant enzymes against transient global cerebral ischemia in gerbils. Anat Cell Biol (2014) 0.82
A mechanistic investigation of the C-terminal redox motif of thioredoxin reductase from Plasmodium falciparum. Biochemistry (2014) 0.81
A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers. Invest New Drugs (2012) 0.81
A direct and continuous assay for the determination of thioredoxin reductase activity in cell lysates. Anal Biochem (2013) 0.81
The conserved redox-sensitive cysteine residue of the DNA-binding region in the c-Rel protein is involved in the regulation of the phosphorylation of the protein. Biochem J (2000) 0.81
Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach. Exp Hematol (2014) 0.81
Genomic and proteomic profiling of oxidative stress response in human diploid fibroblasts. Biogerontology (2008) 0.80
Low doses of selenium specifically stimulate the repair of oxidative DNA damage in LNCaP prostate cancer cells. Free Radic Res (2012) 0.80
Sulforaphane-induced transcription of thioredoxin reductase in lens: possible significance against cataract formation. Clin Ophthalmol (2013) 0.79
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models. Cancer Med (2016) 0.79
Ageing gender-specific "Biomarkers of Homeostasis", to protect ourselves against the diseases of the old age. Immun Ageing (2014) 0.79
High-level expression of the antimicrobial peptide plectasin in Escherichia coli. Curr Microbiol (2010) 0.79
Augmented S-nitrosylation contributes to impaired relaxation in angiotensin II hypertensive mouse aorta: role of thioredoxin reductase. J Hypertens (2011) 0.79
Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science (1997) 16.09
AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci (1995) 14.81
Hydroperoxide metabolism in mammalian organs. Physiol Rev (1979) 14.13
A model for p53-induced apoptosis. Nature (1997) 11.38
ENZYMATIC SYNTHESIS OF DEOXYRIBONUCLEOTIDES. IV. ISOLATION AND CHARACTERIZATION OF THIOREDOXIN, THE HYDROGEN DONOR FROM ESCHERICHIA COLI B. J Biol Chem (1964) 4.36
Thioredoxin-dependent peroxide reductase from yeast. J Biol Chem (1994) 4.22
Selenocysteine. Annu Rev Biochem (1996) 4.08
Thioredoxin and thioredoxin reductase. Methods Enzymol (1995) 4.06
Knowing when not to stop: selenocysteine incorporation in eukaryotes. Trends Biochem Sci (1996) 3.72
Modulation of the fate of cytoplasmic mRNA by AU-rich elements: key sequence features controlling mRNA deadenylation and decay. Mol Cell Biol (1997) 3.54
Biochemistry of oxygen toxicity. Annu Rev Biochem (1989) 3.26
Type I iodothyronine deiodinase is a selenocysteine-containing enzyme. Nature (1991) 3.06
Rat liver thioredoxin and thioredoxin reductase: purification and characterization. Biochemistry (1982) 2.93
Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem (1998) 2.72
Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc Natl Acad Sci U S A (1996) 2.33
Reduction of disulfides by thioredoxin. Exceptional reactivity of insulin and suggested functions of thioredoxin in mechanism of hormone action. J Biol Chem (1979) 2.31
Crystal structure of Escherichia coli thioredoxin reductase refined at 2 A resolution. Implications for a large conformational change during catalysis. J Mol Biol (1994) 2.23
Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res (1993) 2.18
Injected cytochrome c induces apoptosis. Nature (1998) 2.05
Cloning and expression of a novel mammalian thioredoxin. J Biol Chem (1997) 1.89
A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. Proc Natl Acad Sci U S A (1996) 1.85
Bovine thioredoxin system. Purification of thioredoxin reductase from calf liver and thymus and studies of its function in disulfide reduction. J Biol Chem (1977) 1.80
Catalytic properties of an Escherichia coli formate dehydrogenase mutant in which sulfur replaces selenium. Proc Natl Acad Sci U S A (1991) 1.80
Selenocysteine insertion or termination: factors affecting UGA codon fate and complementary anticodon:codon mutations. Nucleic Acids Res (1994) 1.77
Sequence of thioredoxin reductase from Escherichia coli. Relationship to other flavoprotein disulfide oxidoreductases. J Biol Chem (1988) 1.74
1-Chloro-2,4-dinitrobenzene is an irreversible inhibitor of human thioredoxin reductase. Loss of thioredoxin disulfide reductase activity is accompanied by a large increase in NADPH oxidase activity. J Biol Chem (1995) 1.64
Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver. J Biol Chem (1999) 1.63
The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli. Proc Natl Acad Sci U S A (1997) 1.56
Selenocysteine confers the biochemical properties characteristic of the type I iodothyronine deiodinase. J Biol Chem (1991) 1.55
Cloning and sequencing of a human thioredoxin reductase. FEBS Lett (1995) 1.50
Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res (1997) 1.47
Ascorbate free radical as a marker of oxidative stress: an EPR study. Free Radic Biol Med (1993) 1.47
Human thioredoxin reductase directly reduces lipid hydroperoxides by NADPH and selenocystine strongly stimulates the reaction via catalytically generated selenols. J Biol Chem (1995) 1.45
Reduction of dehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase. J Biol Chem (1997) 1.43
Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate selenocysteine residue. J Biol Chem (1998) 1.42
Human p53 inhibits growth in Schizosaccharomyces pombe. Mol Cell Biol (1992) 1.38
The effect of H2O2 upon thioredoxin-enriched lens epithelial cells. J Biol Chem (1988) 1.36
Mechanism and structure of thioredoxin reductase from Escherichia coli. FASEB J (1995) 1.35
Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin. J Biol Chem (1994) 1.33
Selenite is a substrate for calf thymus thioredoxin reductase and thioredoxin and elicits a large non-stoichiometric oxidation of NADPH in the presence of oxygen. Eur J Biochem (1992) 1.31
Regulation of human thioredoxin reductase expression and activity by 3'-untranslated region selenocysteine insertion sequence and mRNA instability elements. J Biol Chem (1999) 1.30
Human mitochondrial thioredoxin reductase cDNA cloning, expression and genomic organization. Eur J Biochem (1999) 1.26
Levels of major selenoproteins in T cells decrease during HIV infection and low molecular mass selenium compounds increase. Proc Natl Acad Sci U S A (1999) 1.25
A hypothesis on the catalytic mechanism of the selenoenzyme thioredoxin reductase. Biochem J (1998) 1.23
Selenodiglutathione is a highly efficient oxidant of reduced thioredoxin and a substrate for mammalian thioredoxin reductase. J Biol Chem (1992) 1.19
Human thioredoxin reductase from HeLa cells: selective alkylation of selenocysteine in the protein inhibits enzyme activity and reduction with NADPH influences affinity to heparin. Proc Natl Acad Sci U S A (1998) 1.18
Efficient reduction of lipoamide and lipoic acid by mammalian thioredoxin reductase. Biochem Biophys Res Commun (1996) 1.18
Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res (1997) 1.17
The role of thioredoxin reductase in the reduction of free radicals at the surface of the epidermis. Biochem Biophys Res Commun (1986) 1.14
Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ (1995) 1.13
Evidence for the participation of Cys558 and Cys559 at the active site of mercuric reductase. Biochemistry (1989) 1.12
Induction of thioredoxin and thioredoxin reductase gene expression in lungs of newborn primates by oxygen. Am J Physiol (1999) 1.12
Thioredoxin reductase activity is decreased by selenium deficiency. Biochem Biophys Res Commun (1997) 1.12
Reduction of the ascorbyl free radical to ascorbate by thioredoxin reductase. J Biol Chem (1998) 1.11
p53 and human cancers. Br Med Bull (1994) 1.11
Purification of human thioredoxin reductase: properties and characterization by absorption and circular dichroism spectroscopy. Biochemistry (1993) 1.09
Cloning, sequencing and functional expression of a novel human thioredoxin reductase. FEBS Lett (1999) 1.09
Efficient transport and accumulation of vitamin C in HL-60 cells depleted of glutathione. J Biol Chem (1997) 1.07
Thioredoxin reductase mediates cell death effects of the combination of beta interferon and retinoic acid. Mol Cell Biol (1998) 1.06
Free radical reduction by thioredoxin reductase at the surface of normal and vitiliginous human keratinocytes. J Invest Dermatol (1986) 1.06
Reductive and oxidative half-reactions of glutathione reductase from Escherichia coli. Biochemistry (1994) 1.06
Aurothioglucose inhibits murine thioredoxin reductase activity in vivo. J Nutr (1999) 1.05
Deletion of the Saccharomyces cerevisiae TRR1 gene encoding thioredoxin reductase inhibits p53-dependent reporter gene expression. J Biol Chem (1998) 1.05
Purification of thioredoxin reductase from the Novikoff rat tumor. Prep Biochem (1977) 1.05
Reductive half-reaction of thioredoxin reductase from Escherichia coli. Biochemistry (1997) 1.04
Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium. Cancer Res (1997) 1.02
NK-lysin, a disulfide-containing effector peptide of T-lymphocytes, is reduced and inactivated by human thioredoxin reductase. Implication for a protective mechanism against NK-lysin cytotoxicity. J Biol Chem (1996) 1.00
Cellular thioredoxin reductase activity is regulated by selenium. Anticancer Res (1998) 1.00
Role of the 3' untranslated region in the regulation of cytosolic glutathione peroxidase and phospholipid-hydroperoxide glutathione peroxidase gene expression by selenium supply. Biochem J (1996) 0.98
Azelaic acid as a competitive inhibitor of thioredoxin reductase in human melanoma cells. Cancer Lett (1987) 0.97
The mechanism of action of the nitrosourea anti-tumor drugs on thioredoxin reductase, glutathione reductase and ribonucleotide reductase. Biochim Biophys Acta (1990) 0.97
Thioredoxin, glutaredoxin, and thioredoxin reductase from cultured HeLa cells. Proc Natl Acad Sci U S A (1981) 0.95
A mutation in a thioredoxin reductase homolog suppresses p53-induced growth inhibition in the fission yeast Schizosaccharomyces pombe. Mol Gen Genet (1996) 0.92
Functional expression of rat thioredoxin reductase: selenocysteine insertion sequence element is essential for the active enzyme. Biochem J (1999) 0.91
Effect of selenium on rat thioredoxin reductase activity: increase by supranutritional selenium and decrease by selenium deficiency. Biochem Pharmacol (1999) 0.91
Enzymatic reduction of alloxan by thioredoxin and NADPH-thioredoxin reductase. Proc Natl Acad Sci U S A (1980) 0.90
Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs. Anticancer Drug Des (1997) 0.89
Thioredoxin reductase from Escherichia coli: evidence of restriction to a single conformation upon formation of a crosslink between engineered cysteines. Protein Sci (1998) 0.88
Selenium supplementation suppresses tumor necrosis factor alpha-induced human immunodeficiency virus type 1 replication in vitro. AIDS Res Hum Retroviruses (1997) 0.88
Selenite and selenate inhibit human lymphocyte growth via different mechanisms. Cancer Res (1996) 0.88
BE-40644, a new human thioredoxin system inhibitor isolated from Actinoplanes sp. A40644. J Antibiot (Tokyo) (1996) 0.87
Heparin-binding properties of selenium-containing thioredoxin reductase from HeLa cells and human lung adenocarcinoma cells. Proc Natl Acad Sci U S A (1997) 0.86
Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin. Relationship to the inhibition of cell proliferation and decreased ribonucleotide reductase activity. Biochem Pharmacol (1992) 0.86
Enzyme-monitored turnover of Escherichia coli thioredoxin reductase: insights for catalysis. Biochemistry (1996) 0.86
The stereospecific suicide inhibition of human melanoma thioredoxin reductase by 13-cis-retinoic acid. Biochem Biophys Res Commun (1989) 0.86
Evidence for a functional relevance of the selenocysteine residue in mammalian thioredoxin reductase. Biofactors (1997) 0.86
Nuclear factor kappaB transactivation is increased but is not involved in the proliferative effects of thioredoxin overexpression in MCF-7 breast cancer cells. Cancer Res (1999) 0.85
Thioredoxin reductase. Role in free radical reduction in different hypopigmentation disorders. Arch Dermatol (1987) 0.85
The 58 kDa mouse selenoprotein is a BCNU-sensitive thioredoxin reductase. FEBS Lett (1997) 0.84
Calcium regulates thioredoxin reductase in human metastatic melanoma. Biochim Biophys Acta (1989) 0.84
Mechanism-based inhibition of thioredoxin reductase by antitumor quinoid compounds. Biochem Pharmacol (1992) 0.83
Cloning and characterization of a novel oxidoreductase KDRF from a human bone marrow-derived stromal cell line KM-102. J Biol Chem (1997) 0.83
Serum selenium and colonic neoplastic risk. Dis Colon Rectum (1995) 0.83
Human thioredoxin reductase gene localization to chromosomal position 12q23-q24.1 and mRNA distribution in human tissue. Genomics (1996) 0.82
Validity of the 'bioassay' for thioredoxin-reductase activity. Arch Dermatol (1988) 0.81
A comment on the absence of calcium regulation of human thioredoxin reductase. FEBS Lett (1993) 0.78
Thioredoxin reductase activity at the surface of human primary cutaneous melanomas and their surrounding skin. Int J Cancer (1991) 0.78
A 3' truncation of myc caused by chromosomal translocation in a human T-cell leukemia is tumorigenic when tested in established rat fibroblasts. Oncogene (1991) 0.77
Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer. Structure (1996) 2.07
Binding of catecholamines to connective tissue and the effect upon the responses of blood vessels to noradrenaline and to nerve stimulation. J Physiol (1973) 1.63
Cloning and sequencing of a human thioredoxin reductase. FEBS Lett (1995) 1.50
Signal transduction during human natural killer cell activation: inositol phosphate generation and regulation by cyclic AMP. J Immunol (1988) 1.49
Free radicals in medicine. II. Involvement in human disease. Mayo Clin Proc (1988) 1.49
Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer (1990) 1.48
Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res (1997) 1.47
Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res (2001) 1.46
Free radicals in medicine. I. Chemical nature and biologic reactions. Mayo Clin Proc (1988) 1.43
3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. J Med Chem (2000) 1.38
Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells. Cancer Res (1996) 1.33
Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin. J Biol Chem (1994) 1.33
Regulation of human thioredoxin reductase expression and activity by 3'-untranslated region selenocysteine insertion sequence and mRNA instability elements. J Biol Chem (1999) 1.30
Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues. Carcinogenesis (1990) 1.28
Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem Pharmacol (1998) 1.22
In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res (1995) 1.20
Relationship of the single-electron reduction potential of quinones to their reduction by flavoproteins. Biochem Pharmacol (1980) 1.20
Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol (2000) 1.20
Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res (1997) 1.17
Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ (1995) 1.13
Human thioredoxin homodimers: regulation by pH, role of aspartate 60, and crystal structure of the aspartate 60 --> asparagine mutant. Biochemistry (1997) 1.10
Purification of human thioredoxin reductase: properties and characterization by absorption and circular dichroism spectroscopy. Biochemistry (1993) 1.09
Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin. Arch Biochem Biophys (2001) 1.09
Cloning, sequencing and functional expression of a novel human thioredoxin reductase. FEBS Lett (1999) 1.09
Molecular modeling studies of the Akt PH domain and its interaction with phosphoinositides. J Med Chem (2001) 1.06
Preferential inhibition of the platelet-derived growth factor receptor tyrosine kinase by staurosporine. J Biol Chem (1990) 1.05
The binding of catecholamines to human serum proteins. Biochem Pharmacol (1975) 1.02
Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium. Cancer Res (1997) 1.02
Anticancer drug pharmacodynamics. Cancer Chemother Pharmacol (1985) 1.01
The effects of pargyline on overflow of transmitter and uptake of noradrenaline in the cat spleen. Br J Pharmacol (1973) 1.00
Cellular thioredoxin reductase activity is regulated by selenium. Anticancer Res (1998) 1.00
Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue. Carcinogenesis (1990) 0.99
Some properties of a preparation of rat colon perfused in vitro through the vascular bed. J Physiol (1971) 0.99
Effect of a single oral dose of methanol, ethanol and propan-2-ol on the hepatic microsomal metabolism of foreign compounds in the rat. Biochem J (1975) 0.98
Iron-EDTA stimulated reduction of indicine N-oxide by the hepatic microsomal fraction, isolated hepatocytes, and the intact rat. Biochem Pharmacol (1982) 0.96
Catalase-overexpressing thymocytes are resistant to glucocorticoid-induced apoptosis and exhibit increased net tumor growth. Cancer Res (2001) 0.96
Tachyphylaxis to ethacrynic acid in the isolated atrium of guinea-pig and its relation to noradrenaline stores. Br J Pharmacol (1978) 0.96
Pulse radiolysis studies of antitumor quinones: radical lifetimes, reactivity with oxygen, and one-electron reduction potentials. Arch Biochem Biophys (1981) 0.96
PI-3-Kinase inhibitors in colorectal cancer. Curr Cancer Drug Targets (2011) 0.95
Quinone-stimulated superoxide formation by subcellular fractions, isolated hepatocytes, and other cells. Mol Pharmacol (1981) 0.95
The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. Biochim Biophys Acta (1994) 0.95
Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci U S A (1994) 0.94
An alternatively spliced form of NQO1 (DT-diaphorase) messenger RNA lacking the putative quinone substrate binding site is present in human normal and tumor tissues. Cancer Res (1995) 0.94
Oxidative inactivation of thioredoxin as a cellular growth factor and protection by a Cys73-->Ser mutation. Biochem Pharmacol (1996) 0.93
Effect of selenium on rat thioredoxin reductase activity: increase by supranutritional selenium and decrease by selenium deficiency. Biochem Pharmacol (1999) 0.91
Calorimetric study of microsomal membrane. J Biol Chem (1977) 0.91
In vitro cytotoxicity of pyrazine-2-diazohydroxide: specificity for hypoxic cells and effects of microsomal coincubation. Invest New Drugs (1988) 0.90
DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs? Br J Cancer (1989) 0.89
Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs. Anticancer Drug Des (1997) 0.89
The accumulation and metabolism of (-)-noradrenaline by cells in culture. Br J Pharmacol (1973) 0.89
Anthracycline-induced inhibition of a calcium action potential in differentiated murine neuroblastoma cells. Cancer Res (1986) 0.89
Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues. Cancer Res (1993) 0.88
The effects of exercise and adrenaline infusion upon the blood levels of propranolol and antipyrine in the horse. J Pharmacol Exp Ther (1978) 0.88
Incomplete hydrolysis of the calcium indicator precursor fura-2 pentaacetoxymethyl ester (fura-2 AM) by cells. Anal Biochem (1988) 0.88
Redox active disulfides: the thioredoxin system as a drug target. Oncol Res (1997) 0.87
Disposition and metabolism of the antitumor agent pyrazine-2-diazohydroxide in mouse and beagle dog. Cancer Chemother Pharmacol (1988) 0.86
Phase I and pharmacokinetic studies of DON. Cancer Treat Rep (1982) 0.86
Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin. Relationship to the inhibition of cell proliferation and decreased ribonucleotide reductase activity. Biochem Pharmacol (1992) 0.86
Disposition of tricyclic nucleoside-5'-monophosphate in blood and plasma of patients during phase I and II clinical trials. Cancer Treat Rep (1986) 0.86
Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man. Drug Metab Rev (1983) 0.86
Nuclear factor kappaB transactivation is increased but is not involved in the proliferative effects of thioredoxin overexpression in MCF-7 breast cancer cells. Cancer Res (1999) 0.85
Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans. Cancer Res (1979) 0.85
The expression of the molecular chaperone calnexin is decreased in cancer cells grown as colonies compared to monolayer. Biochem Biophys Res Commun (1997) 0.85
Redox control of caspase-3 activity by thioredoxin and other reduced proteins. Biochem Biophys Res Commun (2000) 0.84
Effect of serum albumin upon the response of the rat isolated superfused anococcygeus muscle to catecholamines and to nerve stimulation. J Pharm Pharmacol (1974) 0.84
Water-soluble organotellurium compounds inhibit thioredoxin reductase and the growth of human cancer cells. Anticancer Drug Des (2000) 0.84
Increased thioredoxin-1 inhibits SSAT expression in MCF-7 human breast cancer cells. Biochem Biophys Res Commun (2003) 0.83
Metabolism and covalent binding of [14C]toluene by human and rat liver microsomal fractions and liver slices. Drug Metab Dispos (1991) 0.83
Mechanism-based inhibition of thioredoxin reductase by antitumor quinoid compounds. Biochem Pharmacol (1992) 0.83
An uptake mechanism for L-noradrenaline in the cat spleen, associated with the nerves but distinct from uptake. J Physiol (1974) 0.83
Histamine-induced intracellular free Ca++, inositol phosphates and electrical changes in murine N1E-115 neuroblastoma cells. J Pharmacol Exp Ther (1988) 0.83
Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase. Cancer Chemother Pharmacol (1999) 0.83
An increase in intracellular free Ca2+ associated with serum-free growth stimulation of Swiss 3T3 fibroblasts by epidermal growth factor in the presence of bradykinin. J Biol Chem (1988) 0.83
3-Deoxy-D-myo-inositol 1-phosphate, 1-phosphonate, and ether lipid analogues as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth. J Med Chem (1998) 0.83
Inhibition of growth factor-dependent inositol phosphate Ca2+ signaling by antitumor ether lipid analogues. Cancer Res (1990) 0.83
An uptake process for L-noradrenaline resistant to desmethylimipramine (DMI) and 17 -estradiol in the cat spleen. J Physiol (1973) 0.83
Down regulation of the expression of the p110, p85 and p55 subunits of phosphatidylinositol 3-kinase during colon cancer cell anchorage-independent growth. Anticancer Res (2000) 0.82
A study of the interaction of tetracycline with human serum lipoproteins and albumin. J Pharm Pharmacol (1974) 0.82
Human thioredoxin reductase gene localization to chromosomal position 12q23-q24.1 and mRNA distribution in human tissue. Genomics (1996) 0.82
Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H: (quinone-acceptor)oxidoreductase. Cancer Chemother Pharmacol (1988) 0.82
Effect of the monoamine oxidase inhibitor pargyline on the uptake of labelled noradrenaline by the cat's spleen. Br J Pharmacol (1971) 0.81
Downregulation of the antioxidant defence during glucocorticoid-mediated apoptosis. Cell Death Differ (1995) 0.81
A redox-inactive thioredoxin reduces growth and enhances apoptosis in WEHI7.2 cells. Biochem Biophys Res Commun (2000) 0.81
Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents. Anticancer Res (1998) 0.81
Dose-dependent pharmacokinetics and cancer chemotherapy. Cancer Chemother Pharmacol (1981) 0.80
Quinoneimines as substrates for quinone reductase (NAD(P)H: (quinone-acceptor)oxidoreductase) and the effect of dicumarol on their cytotoxicity. Biochem Pharmacol (1987) 0.80
Comparative studies of the in vitro metabolism and covalent binding of 14C-benzene by liver slices and microsomal fraction of mouse, rat, and human. Drug Metab Dispos (1990) 0.80
Synthesis and biology of 1D-3-deoxyphosphatidylinositol: a putative antimetabolite of phosphatidylinositol-3-phosphate and an inhibitor of cancer cell colony formation. J Med Chem (1995) 0.80
Some characteristics of the uptake process in the isolated blood perfused cat spleen resistant to desmethylimipramine and 17- -oestradiol. Br J Pharmacol (1973) 0.80
Protection against adriamycin-induced skin necrosis in the rat by dimethyl sulfoxide and alpha-tocopherol. Cancer Res (1981) 0.80
Role of metabolism and oxidation-reduction cycling in the cytotoxicity of antitumor quinoneimines and quinonediimines. Cancer Res (1987) 0.80
Toxicity and pharmacokinetics of a pyrrolizidine alkaloid, indicine N-oxide, in humans. Cancer Res (1979) 0.79
Enhanced mobilization of intracellular Ca2+ induced by halothane in hepatocytes isolated from swine susceptible to malignant hyperthermia. Anesthesiology (1991) 0.79
The effect of inhibitors of alcohol metabolism upon the changes in the hepatic microsomal metabolism of foreign compounds produced by the acute administration of some alcohols to the rat. Biochem Pharmacol (1976) 0.79
A versatile approach to PI(3,4)P2, PI(4,5)P2, and PI(3,4,5)P3 from L-(-)-quebrachitol. Org Lett (2000) 0.79
A comment on the absence of calcium regulation of human thioredoxin reductase. FEBS Lett (1993) 0.78
Biochemical, structural, and biological properties of human thioredoxin active site peptides. FEBS Lett (1994) 0.78
Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous i.v. infusion. Cancer Treat Rep (1987) 0.78
Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues. Cancer Chemother Pharmacol (1994) 0.78
Transient increases of intracellular Ca2+ induced by volatile anesthetics in rat hepatocytes. Cell Calcium (1990) 0.78